Vasculitis & polymyalgia rheumatica
Serum Wnt3A levels are significantly associated with cross-sectional vasculitis activity and end-stage kidney disease during follow-up of patients with antineutrophil cytoplasmic antibody-associated vasculitis
Main finding · ESKDResult — go to the resultRelative risk 3.867Authors' conclusion
This study is the first to demonstrate the clinical potential of serum Wnt3A levels at diagnosis for estimating cross-sectional activity and partially predicting the advancement to ESKD during follow-up in patients with AAV.
Study context
- Population
- Patients newly diagnosed with AAV at a tertiary hospital (median age 63.5 years; 40% male)
- Participants
- 80 patients
- Exposure
- Serum Wnt3A ≥407.1 pg/mL vs lower serum Wnt3A levels
- Outcome
- Association of serum Wnt3A at diagnosis with cross-sectional activity (BVAS) and poor outcomes (all-cause mortality, ESKD) during follow-up
Methodological detailssingle-centre
- Single-centre
Main finding
ESKD
Relative risk
3.867
As reported in the abstract
Observational data: associations, not effects.
Further findings
Correlation with acute-phase reactants and serum albumin
- Serum Wnt3A at diagnosis significantly correlated with cross-sectional acute-phase reactants and serum albumin
Original publication
Serum Wnt3A levels are significantly associated with cross-sectional vasculitis activity and end-stage kidney disease during follow-up of patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol. Published 4 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →